Insilico Medicine
Insilico Medicine is a clinical-stage biotech company using generative AI for drug discovery. Its platform includes PandaOmics for target identification, with public pipelines covering fibrosis and tumors. The drugs under research have not been marketed yet and should be taken under medical advice.
Updated: 2026-10-26
What is Insilico Medicine?
Insilico Medicine is a clinical-stage biotechnology company driven by generative AI (stock code: 3696 on the Hong Kong Stock Exchange). Its mission is to reinvent drug discovery and development with generative artificial intelligence, shorten the time and cost of bringing life-saving medicines to patients, and focus on targets and new molecules related to aging-related diseases. Unlike AI companies that "sell tools", it builds its own product pipeline and advances AI discoveries into human clinical trials.
Who is it for?
- Pharmaceutical and biotech companies looking for cooperation or licensing with AI platforms.
- R&D teams in need of support for target discovery, molecule generation and indication expansion.
- Research institutions focusing on new mechanisms such as aging, fibrosis and tumors.
- Investors and industry observers tracking the progress of AI-driven drug discovery.
- Patient groups participating in its clinical trials and assessed for enrollment by doctors.
Key features
6Generative Drug Discovery Platform
The company states that it builds an end-to-end pipeline from target discovery to candidate molecules using generative AI and automation, and trains AI with big data to identify new targets and design and optimize novel molecules.
PandaOmics
An AI target discovery and indication expansion platform, which, according to the company, can be used for the "indication expansion strategy" of existing pipelines to match existing molecules to new disease areas.
Aging and Disease Modeling
Identifies diseases by taking aging as the entry point, trains AI to integrate multi-omics data for target discovery, and launches research directions such as virtual cells and biological age.
Clinical-stage Pipeline
Public candidate drugs include Rentosertib (ISM001-055) for idiopathic pulmonary fibrosis, and the company officially stated that its Phase III trial GENESIS-IPF-3 completed the first dose administration in 2026.
Multi-disease Portfolio Layout
Public targets cover fibrosis (TNIK), oncology (USP1, MAT2A, TEAD, ENPP1, CDK12, FGFR2/3, etc.), inflammation and COVID-19-related directions.
Academic Endorsements
Its scientific advisors include Michael Levitt, a Nobel laureate in Chemistry, and the company has published research in journals such as *Nature* and the *Journal of Medicinal Chemistry* in collaboration with multiple institutions.
How to use Insilico Medicine
- All of these are drugs under research, most of which are still in the preclinical or early clinical stage, not yet marketed, and their efficacy and safety to be verified.
- Any medication use must follow medical advice.
- "AI discovery" does not equal "approved": When reading news, distinguish between the disclosure of platform capabilities and the status of regulatory approval, and avoid misinterpreting clinical progress as a conclusion about market launch.
- Partners should first verify the data, models and the validation methodology used in the experiments (officially stated to be mostly verified through rigorous experiments) before conducting due diligence.
- For patients: Eligibility for enrollment is determined by the attending physician and trial centers.
- do not contact on your own to request medication.
- The company's pipeline and stock price information change rapidly, and official judgments shall be based on the announcements of the Hong Kong Stock Exchange and the press releases on the official website.
Traffic & popularity
Data month Sep 2026
Insilico Medicine receives about 19.8K visits per month and ranks #1,729,164 worldwide.
Monthly visits
12 monthsTraffic sources
- Search59.9%
- Direct26.7%
- Referrals7.4%
- AI assistants3.5%
- Social1.9%
- Other0.6%
Top countries
- United States50.8%
- Hong Kong, China10.4%
- Germany5.4%
- India3.7%
- Belgium2.6%
Estimated from third-party traffic data.
Similar tools
XtalPiAn AI and robotics-driven pharmaceutical R&D platform enterprise, officially stated that it takes Agentic AI as the intelligent hub, uses more than 200 vertical-domain AI models for predictive design, and has laboratory robots complete wet experiments, forming a self-iterative R&D closed loop of dry and wet experiments.
TempusTempus is an AI precision medicine company founded by Eric Lefkofsky. It provides gene sequencing, the Tempus One assistant and the Lens platform, and uses multimodal data to assist oncologists in decision-making.
AidocAidoc is a clinical AI platform for healthcare, equipped with FDA-certified radiology and cardiovascular algorithms. It converts clinical signals into actionable decision support and faster care, covering departments such as radiology, cardiology, and neurology.
BioMapA life science large model enterprise, officially stating that it has independently developed the xTrimo basic model and the BioMap OS dry-wet closed-loop discovery system, supports data insights and de novo design, and provides discovery services such as antibodies and proteins to pharmaceutical companies and scientific research institutions.
DeepTechAn AI for Science enterprise, officially stating that it takes DeepShine·Yuzhi Scientific Discovery Intelligent Engine as the foundation, builds tools such as Bohr Scientific Navigation and Lebesgue Intelligent Computing and scientific intelligent agents, targeting basic scientific research and drug and material R&D.